Joint modeling of monocyte HLA‐DR expression trajectories predicts 28‐day mortality in severe SARS‐CoV ‐2 patients
CPT: Pharmacometrics & Systems Pharmacology · 2024-07 · 13 (7) · 1130-1143
DOI: 10.1002/psp4.13145 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 05.06.2024. Verfasst von Gaelle Baudemont und 19 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, Paris, France. Hauptthemen laut MEDLINE: COVID-19, Monocytes, HLA-DR Antigens. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The recent SarsCov2 pandemic has disrupted healthcare system notably impacting intensive care units (ICU). In severe cases, the immune system is dysregulated, associating signs of hyperinflammation and immunosuppression. In the present work, we investigated, using a joint modeling approach, whether the trajectories of cellular immunological parameters were associated with survival of COVID‐19 ICU patients. This study is based on the REA‐IMMUNO‐COVID cohort including 538 COVID‐19 patients admitted to ICU between March 2020 and May 2022. Measurements of monocyte HLA‐DR expression (mHLA‐DR), counts of neutrophils, of total lymphocytes, and of CD4+ and CD8+ subsets were performed five times during the first month after ICU admission. Univariate joint models combining survival at day 28 (D28), hospital discharge and longitudinal analysis of those biomarkers’ kinetics with mixed‐effects models were performed prior to the building of a multivariate joint model. We showed that a higher mHLA‐DR value was associated with a lower risk of death. Predicted mHLA‐DR nadir cutoff value that maximized the Youden index was 5414 Ab/C and led to an AUC = 0.70 confidence interval (95%CI) = [0.65; 0.75] regarding association with D28 mortality while dynamic predictions using mHLA‐DR kinetics until D7, D12 and D20 showed AUCs of 0.82 [0.77; 0.87], 0.81 [0.75; 0.87] and 0.84 [0.75; 0.93]. Therefore, the final joint model provided adequate discrimination performances at D28 after collection of biomarker samples until D7, which improved as more samples were collected. After severe COVID‐19, decreased mHLA‐DR expression is associated with a greater risk of death at D28 independently of usual clinical confounders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Université Paris Cité and Université Sorbonne Paris Nord, Inserm, IAME, Paris, France.
- Département d'Epidémiologie Biostatistique et Recherche Clinique, AP-HP.Nord, Hôpital Bichat, Paris, France.
- Centre d'Investigations Cliniques-Epidémiologie Clinique 1425, INSERM, Hôpital Bichat, Paris, France.
- Immunology Laboratory, Hospices Civils de Lyon, Edouard Herriot Hôpital, Lyon, France.
- Joint Research Unit HCL-bioMérieux, EA 7426 "Pathophysiology of Injury-Induced Immunosuppression" (Université Claude Bernard Lyon 1 - Hospices Civils de Lyon - bioMérieux), Lyon, France.
- Medical intensive Care Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.
ORCID-Profile: Gaelle Baudemont, Coralie Tardivon, Guillaume Monneret, Martin Cour, Jean-Christophe Richard, Morgane Gossez, Florent Wallet, Marie-Charlotte Delignette, Marielle Buisson, Anne-Claire Lukaszewicz, Laurent Argaud, Cédric Laouenan, Julie Bertrand, Fabienne Venet
Zitieren
APA
Baudemont, G., Tardivon, C., Monneret, G., Cour, M., Rimmelé, T., Garnier, L., Yonis, H., Richard, J. C., Coudereau, R., Gossez, M., Wallet, F., Delignette, M. C., Dailler, F., Buisson, M., Lukaszewicz, A. C., Argaud, L., Laouenan, C., Bertrand, J., Venet, F., & RICO study group (2024). Joint modeling of monocyte HLA‐DR expression trajectories predicts 28‐day mortality in severe SARS‐CoV ‐2 patients. CPT: Pharmacometrics & Systems Pharmacology, 13(7), 1130-1143. https://doi.org/10.1002/psp4.13145
Vancouver
Baudemont G, Tardivon C, Monneret G, Cour M, Rimmelé T, Garnier L, et al. Joint modeling of monocyte HLA‐DR expression trajectories predicts 28‐day mortality in severe SARS‐CoV ‐2 patients. CPT: Pharmacometrics & Systems Pharmacology. 2024;13(7):1130-1143. doi:10.1002/psp4.13145
BibTeX
@article{Baudemont2024,
author = {Baudemont, Gaelle and Tardivon, Coralie and Monneret, Guillaume and Cour, Martin and Rimmelé, Thomas and Garnier, Lorna and Yonis, Hodane and Richard, Jean-Christophe and Coudereau, Remy and Gossez, Morgane and Wallet, Florent and Delignette, Marie-Charlotte and Dailler, Frederic and Buisson, Marielle and Lukaszewicz, Anne-Claire and Argaud, Laurent and Laouenan, Cédric and Bertrand, Julie and Venet, Fabienne and RICO study group, RICO study group},
title = {Joint modeling of monocyte HLA‐DR expression trajectories predicts 28‐day mortality in severe SARS‐CoV ‐2 patients},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2024},
volume = {13},
number = {7},
pages = {1130--1143},
doi = {10.1002/psp4.13145}
}
EUVIMED